期刊文献+

胃肠间质瘤46例临床分析 被引量:2

Clinical analysis on 46 cases with gastrointestinal stromal tumor
原文传递
导出
摘要 目的探讨胃的胃肠间质瘤(GIST)临床特点和影响预后的因素。方法回顾性分析手术治疗的46例胃GIST患者的临床、病理资料。结果病变部位:胃底贲门17例(37.0%),胃体22例(47.8%),胃窦部5例(10.9%),占据胃壁两个部位2例(4.3%)。肿瘤直径1.0-15.0cm。全组患者均行肿瘤完整切除;淋巴结清扫11例,未发现转移淋巴结。免疫组织化学染色,CD117阳性率91.3%(42/46),CD34阳性率80.4%(37/46)。40例患者获随访,1、3和5年生存率分别为94.7%、80.2%和56.6%。单因素分析显示,Fletcher分级、肿瘤大小、肿瘤侵犯其他脏器、转移和口服甲磺酸伊马替尼对生存率有影响(P<0.05或P<0.01)。结论手术是治疗胃GIST的主要方法。转移是影响胃GIST预后的独立危险因素。Fletcher分级是判断胃GIST生物学行为及预后简单有效的方法。 Objective To investigate the clinicopathologecal characteristics and the factors to influence the prognosis of gastric gastrointestinal stromal tumors(GIST) in the stomach.MethodsThe clinicopathological data of 46 patients with gastric GIST were analyzed retrospectively.ResultsTumor located at the cardia or fundus in 17 cases(37.0%),the stomach body in 22 cases(47.8%),the antrum in 5 cases(10.9%),and at two regions in 2 cases(4.3%).Tumor sized 1.0 to 15.0 cm.All patients underwent complete tumor resection,of whom 11 cases underwent lymph node dissection without lymph node metastasis.The positive rate was 91.3%(42/46) for CD 117 and 80.4%(37/46) for CD34.The 1-,3-and 5-year survival rates of the 40 cases with follow up were 94.7%,80.2%,and 56.6%,respectively.Univariate analysis revealed that the differences in Fletcher classification,tumor size,infiltration to surrounding tissues,preoperative metastasis,and adjuvant postoperative therapy with imatinib were related to the survival rates(P〈0.05 or P〈0.01).Conclusion Surgery is the main therapy for gastric GIST.Metastasis is an independent factor for predicting the prognosis of gastric GIST.Fletcher classification can be used to evaluate the biological behavior and prognosis.
作者 钟广俊
出处 《江苏医药》 CAS CSCD 北大核心 2012年第2期158-160,共3页 Jiangsu Medical Journal
关键词 胃肠间质瘤 甲磺酸伊马替尼 Gastrointestinal stromal tumors Imatinib mesylate
  • 相关文献

参考文献11

  • 1Cichoz-Lach H,Kasztelan-Szczerbinska B,Slomka M.Gastro-intestinal stromal tumors:epidemiology,clinical picture,diagnosis,prognosis and treatment[J].Pol Arch Med Wewn,2008,118(4):216-221.
  • 2Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastro-intestinal stromal tumors:a consensus approach[J].HumPathol,2002,33(5):459-465.
  • 3Bauer S,Corless CL,Heinrich MC,et al.Response to imatinibmesylate of a gastrointestinal stromal tumor with very lowexpression of KIT[J].Cancer Chemother Pharmacol,2003,51(3):261-265.
  • 4戎龙,万远廉,年卫东,柳萍,梁进雨.胃间质瘤63例临床分析[J].中华胃肠外科杂志,2009,12(1):24-27. 被引量:11
  • 5Mochizuki Y,Kodera Y,Ito S,et al.Treatment and riskfactors for recurrence after curative resection of gastro-intestinal stromal tumors of the stomach[J].World J Surg,2004,28(9):870-875.
  • 6Carboni F,Carlini M,Scardamaglia F,et al.Gastrointestinalstromal tumors of the stomach.A ten-year surgical experience[J].J Exp Clin Cancer Res,2003,22(3):379-384.
  • 7DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastro-intestinal stromal tumors:recurrence patterns and prognosticfactors for survival[J].Ann Surg,2000,231(1):51-58.
  • 8Miettinen M,Sobin LH,Lasota J.Gastrointestinal stromaltumors of the stomach:a clinicopathologic,immunohisto-chemical,and molecular genetic study of 1765cases with long-term follow-up[J].Am J Surg Pathol,2005,29(1):52-68.
  • 9白月奎,邵永孚,石素胜,高燕宁,孙耘田,程书钧,刘秀云.胃肠道间质瘤预后多因素分析[J].中华肿瘤杂志,2005,27(10):598-601. 被引量:22
  • 10Choi WH,Kim S,Hyung WJ,et al.Long-surviving patientswith recurrent GIST after receiving cytoreductive surgerywith imatinib therapy[J].Yonsei Med J,2009,50(3):437-440.

二级参考文献22

  • 1娄越亮,陈华,张燮良,战忠利.96例胃肠道间质瘤临床诊治分析[J].中华肿瘤杂志,2004,26(7):437-439. 被引量:25
  • 2何裕隆.胃肠间质瘤外科治疗的选择[J].中华胃肠外科杂志,2006,9(1):15-16. 被引量:29
  • 3詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 4Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol, 2005, 16:566-578.
  • 5Parfitt JR, Streutker C J, Riddell RH, et al. Gastrointestinal stromal tumors: a contemporary review. Pathol Res Pract, 2006, 202 : 837-847.
  • 6Fusaroli P, EK, R.N.A.L.D, et al. Gastrointestinal stromal tumors: Long term follow up by EUS up to 13 years. Digestive and Liver Disease, 2002, 34 : A116.
  • 7Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol, 2002, 33:466-77.
  • 8Demetri GD, yon Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347:472-480.
  • 9Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7:507-519.
  • 10Tran T, Davila JA, E1-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol, 2005, 100: 162-168.

共引文献29

同被引文献29

  • 1徐守余,杨道华,邱承敏,张鸣,何佩锋,柳堤.胃肠道间质瘤24例临床病理及免疫组化分析[J].肿瘤,2007,27(6):473-475. 被引量:4
  • 2史恩溢,侯英勇,谭云山,周晓燕,蔡旭,陆永明,朱雄增.局限性胃肠道间质瘤危险程度分级标准的应用与评价[J].中华病理学杂志,2007,36(10):649-653. 被引量:18
  • 3Dow N,Giblen G,Sobin LH,Miettinen M.Gastrointestinal stromal tu- mors : differentialdiagnosis[J].Semin Diagn Pathol, 2006,23 : 111-119.
  • 4Miettinen M ,Sarlomo-Rikala M ,Lasota J.Gastrointestinalstromal tu- mors[J].Ann Chir Gynaeeol, 1998,87 (4) : 278-281.
  • 5Atila K,Arslan NC, Derici S, et al. Neutrophil-to-lymphocyte rati-o:could it be used in the clinic.as prognostic marker forgastroint-estinal stromal tumor E J 1. Hepatogastroenterology, 2014, 61 (134):1649-1653.
  • 6Bongiovanni A, Ricei M, Riva N, et al. Pleural effusion in a pa-tient with metastatic gastrointestinal stromal tumo treated with imatinib:ease report ~ J]. Future Oncol, 2014, 10 (15):2423-2427.
  • 7Zhao WY,Zhuang C ,Xu J,et al. HER4 is a novel prognostic bio-marker in gastrointestinal stromal tumor specifically originated from stomach[J~. Am J Cancer Res,2014,4(6):838-849.
  • 8Chang DK. A high risk group in the modified national institutes of health consensus criteria for thegastrointestinal stromal tumor:a clear indication of the adjuvant imatinib[J]. Intest Res,2014,12 (3):176-177.
  • 9Yamamoto H, Oda Y. Molecular pathological classification and its clinicopathological significance in gastrointestinal stromal tumor [J]. Fukuoka Igaku Zasshi ,2014,105 (8):157-165.
  • 10Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors:clinical evidence and place in therapy[J]. Ther Adv Med Oncol, 2014,6 (5):222-228.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部